Myriad Genetics myPath Melanoma test receives Medicare coverage

Myriad Genetics announced that the Medicare administrative contractor Palmetto GBA MolDx has issued a final local coverage determination for the myPath Melanoma test to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology. The myPath Melanoma test analyzes 23 genes and has proven to be highly accurate in multiple studies at distinguishing melanoma from benign moles.
https://thefly.com/landingPageNews.php?id=2879171